Vaccines and kids 2

COVID-19 Vaccine Requirements: Considerations for U.S. Clinical Trial Participants

Nov 03, 2021 | Katherine Waters, Victoria Thompson

As the COVID-19 response evolves, vaccine requirements, sometimes referred to as mandates, are increasingly being used as a tool to improve vaccine uptake. Vaccine requirements, especially when used in specific settings such as the workplace or healthcare facilities, are a long-standing and proven public health strategy for increasing vaccination coverage and decreasing the incidence of morbidity and mortality associated with vaccine-preventable diseases, such as COVID-19. One main way in which vaccine requirements are being utilized is through the Biden Administration’s COVID-19 action plan which outlines vaccination requirements for the following groups:

  • Employers with 100 or more employees are to require vaccination or ensure weekly negative tests for unvaccinated employees;
  • Healthcare workers at Medicare and Medicaid participating hospitals and health care facilities; and
  • Federal workers and contractors that do business with the federal government.

In addition to the COVID-19 vaccines that are authorized and recommended for use in the United States (Moderna, Pfizer, and Janssen), some individuals may have been vaccinated for COVID-19 through a clinical trial in which the vaccine has not yet been approved in the U.S. For the purposes of vaccine requirements, it’s important to understand how to determine if a person who has been vaccinated through one of these trials is considered fully vaccinated. To do so, the Centers for Disease and Control and Prevention (CDC) has issued interim guidance for those who have been vaccinated as part of a clinical trial for a COVID-19 vaccine that is not currently approved or authorized by the Food and Drug Administration (FDA). Current CDC guidance is below.

A person vaccinated against COVID-19 as part of a clinical trial in the U.S. is considered fully vaccinated:

  • Two weeks after receiving the full vaccination series AND
  • The vaccine given is confirmed to have been an active vaccine, not a placebo dose AND
    • The vaccine is listed for emergency use by the World Health Organization (currently the AstraZeneca COVID-19 vaccine meets these criteria) OR
    • The vaccine efficacy has been independently confirmed (currently the Novavax COVID-19 vaccine meets these criteria)

As always, please reference CDC and FDA for the most current information regarding which COVID-19 vaccines have been approved in the United States. For additional information and resources, please see the relevant links below.

Biden Administration’s COVID-19 action plan

Different COVID-19 Vaccines | CDC

COVID-19 Vaccines | FDA

Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

COVID-19 Workplace Safety: Guidance for Federal Contractors and Subcontractors


About Katherine Waters

More posts by Katherine Waters

About Victoria Thompson

Victoria Thompson is a Senior Program Analyst on the Immunization Team at NACCHO.

More posts by Victoria Thompson

Related Posts

  • HIV, STI, & Viral Hepatitis

NACCHO partners with Altarum on “Congenital Syphilis...

A study was conducted among women who received prenatal care in a current or...

Jul 10, 2025 | Rebekah Horowitz

NACCHO partners with Altarum on “Congenital Syphilis...

  • HIV, STI, & Viral Hepatitis

New Report on Routine Opt-Out Syphilis Testing in...

NACCHO funded 3 LHD’s to partner with their local women’s jail to evaluate the...

Jun 03, 2025 | Rebekah Horowitz

New Report on Routine Opt-Out Syphilis Testing in...

FLEXED LC Applications Open
  • ID Featured, Infectious Disease

Join NACCHO’s Flexible Local Epidemiology for X-factor...

Learn more about NACCHO’s Flexible Local Epidemiology for X-factor Emerging...

May 30, 2025 | Jaclyn Abramson

Join NACCHO’s Flexible Local Epidemiology for X-factor...

Webinar
  • Webinar, Infection, Prevention, and Control

Strengthening Public Health / Healthcare Relationships...

On June 24, 2025, NACCHO hosted a 4-hour workshop on strengthening public...

May 23, 2025 | Candice Young

Strengthening Public Health / Healthcare Relationships...

  • HIV, STI, & Viral Hepatitis

New Report Highlights Opportunities and Lessons Learned...

This report offers concrete insights and recommendations for local health...

May 19, 2025 | Kat Kelley

New Report Highlights Opportunities and Lessons Learned...

Webinar
  • Webinar, Infection, Prevention, and Control

Data Use and Visualization for IPC: A Three-Part...

NACCHO hosted a comprehensive training series for LHD staff engaged in...

May 19, 2025 | Candice Young

Data Use and Visualization for IPC: A Three-Part...

Hepatitis Awareness Month 2025 Blog Post Image
  • HIV, STI, & Viral Hepatitis

Hepatitis Awareness Month 2025

Hepatitis Awareness Month is time to raise awareness about viral hepatitis and...

May 06, 2025 | Kat Kelley

Hepatitis Awareness Month 2025

AI Webinar Series
  • Webinar

Two-Part Webinar Series: Building AI Readiness in Public...

NACCHO hosted a two-part webinar series on how public health professionals can...

May 05, 2025 | Gelilawit Tamrat, Kristen Ross

Two-Part Webinar Series: Building AI Readiness in Public...

  • HIV, STI, & Viral Hepatitis

CDC Releases 2023 Viral Hepatitis Surveillance and 2025...

CDC reported on trends in hepatitis A, B, and C as well as national progress...

Apr 30, 2025 | Kat Kelley

CDC Releases 2023 Viral Hepatitis Surveillance and 2025...

Back to Top